Drug resistance in leprosy: an update following 70 years of chemotherapy
Paris; s.n; 2022. 9 p. tab.
Não convencional
em Inglês
| HANSEN, SES-SP, HANSENIASE, SESSP-ILSLPROD, SES-SP, SESSP-ILSLACERVO, SES-SP
| ID: biblio-1402103
Biblioteca responsável:
BR191.1
Localização: BR191.1; 9843/S
ABSTRACT
Leprosy is one of the oldest infectious diseases, reported for more than 2000 years. Leprosy elimination goal as a public health problem set by the World Health Organization, aiming for a global prevalence rate < 1 patient in a population of 10,000, was achieved in 2000 mainly thanks to the worldwide use of leprosy drugs starting in the 1980s and their access at no cost for patients since 1995. However, around 200,000 new cases are still reported each year, particularly in India, Brazil, and Indonesia. As with other bacteria of medical interest, antimicrobial resistance is observed in Mycobacterium leprae strains in several parts of the world, despite multidrug therapy being the recommended standard leprosy treatment to avoid resistance selection since 1982. Therefore, identifying and monitoring resistance is necessary. We provide an overview of the historical facts that led to the current drug resistance situation, the antibiotics effective against M. leprae, their mechanisms of action and resistance, and resistance detection methods. We also discuss therapeutic management of the resistant cases, new genes with potential roles in drug resistance and bacterial adaptation, new drugs under investigation, and the risk for resistance selection with the chemoprophylaxis measures.
Texto completo:
Disponível
Tema:
Complicações
/
Epidemiologia
/
Geral
/
Tratamento Medicamentoso
Bases de dados:
HANSEN
/
HANSENIASE
/
Sec. Est. Saúde SP
Assunto principal:
Resistência a Medicamentos
/
Tratamento Farmacológico
/
Hanseníase
/
Biologia Molecular
/
Mycobacterium leprae
Tipo de estudo:
Estudo prognóstico
/
Fatores de risco
Idioma:
Inglês
Ano de publicação:
2022
Tipo de documento:
Não convencional
Similares
MEDLINE
...
LILACS
LIS